Gradalis Publishes Key Findings on Clonal Signals in Cancer Immunotherapy

Gradalis, Inc., a leader in personalized cancer immunotherapy, has published groundbreaking research in Scientific Reports, shedding light on how clonal tumor signals can enhance immunotherapy precision. The study validates the company’s exome sequencing and bioinformatics pipeline, which identifies genetic patterns driving tumor growth. By focusing on clonal tumor mutation burden (cTMB), clonal neoantigens (cNEO), and intratumor heterogeneity (ITH), Gradalis aims to refine patient selection for immunotherapies like its investigational treatment, Vigil. This work underscores the potential of targeting stable clonal signals to improve immunotherapy outcomes across multiple cancer types.

John Nemunaitis, M.D., Gradalis’ Chief Scientific Officer, emphasized that clonal tumor signals offer a crucial molecular target for attacking cancer cells. The study, conducted in collaboration with Frontage Laboratories, demonstrated that Vigil maintains these genetic markers, reinforcing its reliability as a therapeutic approach. Lead author David Willoughby, Ph.D., noted that their exome sequencing platform is designed for high-throughput patient identification, potentially optimizing immunotherapy strategies. With this research, Gradalis continues to advance the field of precision oncology, aiming to revolutionize cancer treatment through enhanced molecular targeting.